US2008227771A1PendingUtilityA1
Delta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Est. expiryOct 11, 2025(expired)· nominal 20-yr term from priority
A61P 9/10A61P 9/00A61P 9/06A61P 9/04C07D 223/16C07B 2200/13A61K 31/55
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A δd-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Claims
exact text as granted — not AI-modified1 . A δd-Crystalline form of ivabradine hydrochloride of formula (I):
2 . The δd-Crystalline form of ivabradine hydrochloride of claim 1 having a powder X-ray diffraction diagram exhibiting peaks at 14.6, 15.3, 17.2, 18.1 and 21.4 deg 2 theta.
3 . The δd-Crystalline form of ivabradine hydrochloride of claim 1 having a powder X-ray diffraction diagram exhibiting peaks at 8.6, 9.1, 10.9 and 11.7 deg 2 theta.
4 . A pharmaceutical composition comprising as active ingredient the δd-crystalline form of ivabradine hydrochloride of claim 1 , in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers.
5 . A method for treating or preventing a condition requiring a bradycardic, such method comprising the step of administering to a living animal body, including a human, a therapeutically effective amount of the δd-crystalline form of ivabradine hydrochloride of claim 1 .
6 . A method for treating or preventing clinical situations of myocardial ischaemia and/or a condition involving rhythm disturbances, such method comprising the step of administering to a living animal body, including a human, a therapeutically effective amount of the δd-crystalline form of ivabradine hydrochloride of claim 1 .
7 . The method of claim 6 , wherein the clinical situation of myocardial ischaemia is selected from angina pectoris, myocardial infarct and associated rhythm disturbances.
8 . The method of claim 6 , wherein the condition involving rhythm disturbances is selected from supraventricular rhythm disturbances and heart failure.Join the waitlist — get patent alerts
Track US2008227771A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.